<DOC>
	<DOCNO>NCT00631800</DOCNO>
	<brief_summary>The purpose study evaluate safety ( include tolerability ) , pharmacokinetics , pharmacodynamics clinical activity BSYX-A110 administer 3-dose regimen Study Days 0 , 7 , 14 .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Pharmacodynamics , Clinical Activity Study VLBW Neonates BSYX-A110</brief_title>
	<detailed_description>This Phase II study randomize , double blind , placebo control study BSYX-A110 low birth weight neonate . A total 80 infant dose study . Participants receive either BSYX-A110 placebo , 60 mg/kg 90 mg/kg . The Study Drug administer 48-120 hour life , 7 day initial dose , 14 day initial dose dose group .</detailed_description>
	<criteria>Patients must meet follow criterion time first infusion ( Day 0 ) : 1 . 48120 hour age , inclusive 2 . Birth weight 7001300 gram 3 . Inpatient Neonatal Intensive Care Unit 4 . Written inform consent obtain parent ( ) legal guardian Multiple gestation : 1 . Siblings multiple gestation may enrol meet entry criterion 2 . No 4 subject birth weight cohort may siblings Patients may none follow first dose : 1 . Survival expect least 1 week infusion 2 . Clinically overt systemic infection , determine history , physical examination , positive culture normally sterile site . ( Infuse infant clinically stable culture negative 48 hour . If evaluate sepsis , decision infuse may defer allow protocol infusion window . Infusions outside protocol window must approve Sponsor . ) 3 . Severe congenital anomaly genetic disorder likely fatal may interfere drug distribution metabolism , determine history and/or physical examination , include limited : i. Trisomy 13 ii . Trisomy 18 iii . Hypoplastic Left Heart Syndrome iv . Omphalocele v. Gastroschesis vi . Holoprosencephaly 4 . Known suspected hepatic renal insufficiency 5 . Clinically uncontrolled seizure 6 . Immunodeficiency due prematurity 7 . A history standard immune globulin administration prior first study drug infusion ( exclude Hepatitis B Immune Globulin , HBIG ) 8 . Any history , infant subject mother , hypersensitivity severe vasomotor reaction immunoglobulin G , blood product 9 . Currently receive , recently receive , plan receive investigational agent could interfere conduct result study ; include enrollment another investigational study product IRBapproved protocol 10 . Expectation patient able follow duration study 11 . Mother serology positive hepatitis B surface antigen</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Hours</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Staphylococcal</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Very Low Birth Weight Infants</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>